Capital Flow Monitor · Sponsors · CIK 2130748
Terremoto Biosciences, Inc.
230 EAST GRAND AVENUE, SUITE 200, SOUTH SAN FRANCISCO, CA, 94080 · 415-535-2787
Biotechnology · Corporation· inc. DELAWARE true 2022
Fit score
—
Offering
$108.6M
Sold
$40.7M
% sold
37.5%
Investors
14
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-04-22 | D ·current | 506(b) | $108.6M | $40.7M | 37.5% | 14 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
-
Charles Baum — Executive Officer / Director, South San Francisco, CA
1 other raise
- Crossbow Therapeutics, Inc. $30.3M of $80.0M · 37.8%
-
James Christensen — Executive Officer / Director, South San Francisco, CA
1 other raise
- TIMBER CLUB MEMBER, LLC $3.1M of $3.2M · 96.2%
- Grace Lu — Executive Officer, South San Francisco, CA
-
Reid Huber — Director, South San Francisco, CA
1 other raise
- Third Rock Ventures VII, L.P. $0 of $750.0M · 0.0%
-
Daniel O'Connell — Director, South San Francisco, CA
2 other raises
- Footnote FM, Inc. $12K of $500K · 2.4%
- Whisker Labs, Inc. $6.6M of $6.6M · 100.0%
-
Peter Thompson — Director, South San Francisco, CA
2 other raises
- Alpheus Medical, Inc. $60.5M of $67.0M · 90.3%
- Sparrow Pharmaceuticals, Inc. $61.8M of $121.4M · 50.9%
-
Michael Goller — Director, South San Francisco, CA
1 other raise
- Precision Neuroscience Corp $250.0M of —
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.